These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 7660508

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
    Bernardini S, Adessi GL, Billerey C, Chezy E, Carbillet JP, Bittard H.
    J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
    [Abstract] [Full Text] [Related]

  • 5. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
    Salinas-Sánchez AS, Lorenzo-Romero JG, Giménez-Bachs JM, Sánchez-Sánchez F, Donate-Moreno MJ, Rubio-Del-Campo A, Hernández-Millán IR, Segura-Martín M, Atienzar-Tobarra M, Escribano-Martínez J.
    Urol Oncol; 2008 Oct; 26(6):620-6. PubMed ID: 18367096
    [Abstract] [Full Text] [Related]

  • 6. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
    Cai T, Nesi G, Boddi V, Mazzoli S, Dal Canto M, Bartoletti R.
    Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
    [Abstract] [Full Text] [Related]

  • 7. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK.
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [Abstract] [Full Text] [Related]

  • 8. Expression of bcl-2 and bcl-X in bladder cancer.
    Kirsh EJ, Baunoch DA, Stadler WM.
    J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
    [Abstract] [Full Text] [Related]

  • 9. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.
    Anticancer Res; 2002 Apr; 22(6B):3759-64. PubMed ID: 12552989
    [Abstract] [Full Text] [Related]

  • 10. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL.
    J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
    Schlichtholz B, Presler M, Matuszewski M.
    Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
    Gumus E, Erdamar S, Demirel G, Horasanli K, Kendirci M, Miroglu C.
    Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
    [Abstract] [Full Text] [Related]

  • 15. Prognosis of transitional cell bladder carcinoma. With special reference to ABH blood group isoantigen expression and DNA analysis.
    Malmström PU.
    Scand J Urol Nephrol Suppl; 1988 Dec; 112():1-55. PubMed ID: 3068792
    [Abstract] [Full Text] [Related]

  • 16. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C.
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [Abstract] [Full Text] [Related]

  • 17. DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder.
    Pantazopoulos D, Ioakim-Liossi A, Karakitsos P, Aroni K, Kakoliris S, Kanavaros P, Kyrkou KA.
    Anticancer Res; 1997 Jun; 17(1B):781-6. PubMed ID: 9066620
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F, Le Frere Belda MA, Quintela R, Hoznek A, Patard JJ, Bellot J, Popov Z, Zafrani ES, Abbou CC, Chopin DK, de Medina SG.
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.